Hereditary amyloidosis represents a group of diseases in which mutant proteins are deposited in various organs leading to their dysfunction. Correct identification of the amyloid-causing protein is critical because this will determine the optimal therapy for the patient. The most common type of hereditary amyloidosis is due to mutant transthyretin (ATTRm) deposition and often presents with heart failure or peripheral neuropathy. We report the first known case of a patient who had amyloidosis both due to a mutant transthyretin (p.Val122Ile) and due to a novel variant in the gelsolin gene (p.Ala578Pro). Both mutant proteins were identified by mass spectrometry analysis of amyloid deposits as well as sequencing of the genes. Molecular dynamic simulations suggest that the gelsolin p.Ala578Pro variant is likely amyloidogenic.
A myloidosis refers to a group of acquired or inherited diseases caused by the deposition of misfolded proteins in various organs, in b-pleated sheet format, leading to their dysfunction. 1 Traditionally, amyloidosis is diagnosed by staining the suspected tissues with Congo red (CR) and observing apple-green birefringence under polarized light. Twenty-five different amyloidogenic proteins are known and most common hereditary forms of amyloidoses include transthyretin (ATTR), gelsolin (AGel), lysozyme (ALys), apolipoprotein AI (AApoAI), AII (AApoAII), CII (AApoCII), and CIII (AApoCIII). 2 Therapeutic options differ considerably between various forms of amyloidoses while there is a considerable overlap between their clinical presentations. Hence, typing the amyloid deposits to accurately determine the causative amyloidogenic protein is critical for prescribing therapy. 3 Here, we describe a patient with a known hereditary ATTR mutation and a novel gelsolin mutation that appears amyloidogenic.
CASE PRESENTATION
A 57-year-old black man presented elsewhere with increasing dyspnea. An echocardiogram demonstrated an ejection fraction of 19%. He was prescribed diuretics and an angiotensin-converting enzyme inhibitor. An endomyocardial biopsy was diagnostic of amyloidosis. Proteomic analysis 4 of the amyloid deposits identified transthyretin (TTR) amyloidosis (ATTR) ( Figure 1A ). The TTR gene sequencing showed a c.424G>A mutation, resulting in a substitution of p.Val122Ile (V122I; Figure 1B ). The corresponding mutant peptide was also detected in the amyloid deposit ( Figure 1C ). This mutation is associated with hereditary amyloidosis with predominant cardiac involvement. The patient did not have any family history of hereditary amyloidosis.
The patient was referred to Mayo Clinic for possible cardiac and liver transplantation. During his evaluation, a CR-positive abdominal fat aspirate confirmed amyloidosis. However, proteomic analysis of this tissue showed gelsolin amyloidosis (AGel) (Figure 2A ). Upper and lower gastrointestinal tract endoscopic biopsies also showed CR positivity, and proteomic analysis of these tissues showed AGel in the descending colon (Figure 2A ). Neither the fat aspirate nor gastrointestinal amyloid deposits contained TTR wild-type or mutant protein (Figure 2A ). Therefore, there was no evidence of overlapping tissue involvement by the 2 different types of amyloid proteins. The patient's only other symptoms were paresthesia in his hands, but Apolipoprotein E OS=Homo sapiens GN=APOE... parent+2H-H2O b9-H2O b9-H2O-H2O y6 y7 y8 y9 he did not have any symptoms or signs of cranial neuropathies, visual symptoms, or skin changes that are typical of AGel amyloidosis. 5 Gelsolin gene sequencing identified a c.1732G>C mutation ( Figure 2B ), resulting in a substitution of p.Ala578Pro. We also detected the corresponding mutant peptide in the fat aspirate amyloid deposits ( Figure 2C ). This mutation was not reported in ExAc and dbSNP databases, ruling out a population polymorphism. Molecular dynamics simulations were performed to assess the effect of p.Ala578Pro on gelsolin's structure and the results were compared with those of 3 known hereditary AGel mutations (p.Gly194Arg, p.Asn211Lys, p.Asp214Tyr; 3-dimensional locations of known and novel AGel mutations shown in Figure 3 ). The simulations demonstrated that all the sequences studied sampled similar large-scale motions, but revealed that amyloid-associated variants lead to increased activation of them. The differential activation of the dominant motions is visualized for WT and A578P using smoothed densities where more intense color indicates greater probability. E-H, We investigated motions of the GSN-L5 (E and G) and GSN-L2 (F and H) domains alone. The motilities of each residue according to PC1 (E and F) and PC3 (G and H) are shown using a color scale where blue indicates small amount of mobility, white an intermediate amount, and red large mobility. For both domains, loops nearby the variant-containing sites exhibit the most mobility. GSN ¼ gelsolin; MD ¼ molecular dynamics; WT ¼ wild type.
simulations was used to quantify the observed dominant motions in full-length gelsolin. A578P leads to enhanced activation of interdomain rotations ( Figure 2D ; PC1-dominant domain rotations are shown in Figure 3 ). We also superimposed the trajectories of each domain independently and a PC analysis was performed to investigate variant-dependent domain motions (Figures 2E-H) . A common feature detected across all amyloid variants was increased mobility of nearby loops. A578P in particular increased the mobility of the short loop connecting the second and third strands of the beta-sheet. This suggested that A578P alters gelsolin dynamics similarly to known amyloidogenic variants. Although the patient had 2 types of amyloidoses, TTR mutation was the cause of his cardiomyopathy and he underwent a combined heart and domino liver transplantation.
DISCUSSION
This is the first report of a patient with 2 mutually exclusive and distinct genetic amyloid deposits: one contains a known hereditary ATTR mutant and another contains AGel with a novel mutation (AGel p.Ala578Pro) that has propensity to misfold (first step toward forming amyloid fibrils). The presence of both these amyloidogenic mutant forms was confirmed at the germline level and in the amyloid deposits.
Liver-derived TTR is a circulating tetrameric protein and both wild-type and mutant TTR have propensity to misfold and assemble into amyloid fibrils. However, amyloidogenic missense mutations in hereditary TTR (ATTRm) destabilize its tetrameric structure: a precursor step toward amyloidogenesis. Deposition of ATTRm fibrils in organs leads to various clinical features, including lengthdependent sensorimotor polyneuropathy, autonomic neuropathy, cardiomyopathy, and occasional renal damage. The V122I (p.Val122.Ile) mutation detected in our patient is known to cause late-onset systemic disease with dominant cardiac involvement, which fits the clinical picture of our patient.
AGel is a rare autosomal-dominant disease arising from misfolding of gelsolin protein due to amyloidogenic mutations. AGel fibers are often deposited in the eyes, skin, and peripheral nerves, resulting in the clinical triad of neurological, ophthalmological, and dermatological findings. Rarely, AGel leads to more systemic disease including renal, cardiac, and pharyngo-oral-dental abnormalities. The age of onset is likely earlier in homozygous patients although the condition does not appear to considerably shorten the lifespan. Four pathogenic AGel mutations have been identified so far (listed in the Results section), and our patient had a novel A578P (p.Ala578Pro) mutation.
The most important neurological finding observed in our patient is distal paresthesia, which has been observed in other AGel patients. Typical AGel peripheral neuropathy is mild and involves distal paresthesia, loss of vibration sense, and absent or decreased tendon reflexes. However, our patient did not have the characteristic slowly progressive cranial neuropathy that manifests in the fourth or fifth decade of life of AGel patients. It is possible that the novel de novo AGel p.Ala578Pro mutation has slower disease progression. However, paresthesia is also observed with ATTRm. Despite this, the presence of the mutated gelsolin peptide in the amyloid deposits provides evidence of its involvement in the disease.
CONCLUSION
Lightning rarely strikes twice. Proteomic analysis of amyloid deposits combined with germline gene sequencing has enabled reliable identification of both hereditary amyloidoses. It is important to distinguish these from nonhereditary systemic amyloidoses such as AL amyloidosis. Because 7% of the clinic population has a monoclonal protein, amyloidosis-defining syndrome may coexist with an M-protein by chance. This fact combined with our unique case highlights the importance of accurately determining the amyloidogenic protein to prescribe the correct treatment. 3 Abbreviations and Acronyms: AGel = gelsolin amyloidosis; ATTR = transthyretin amyloidosis; CR = Congo red; PC = principal component; TTR = transthyretin
